Strengthening the eye's outer layer to slow nearsightedness
Scleral Remodeling in Myopia
Looking at whether boosting natural strengthening of the eye's outer coat can slow worsening nearsightedness for people with progressive myopia.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11285224 on NIH RePORTER |
What this research studies
Researchers are exploring how the white of the eye (the sclera) becomes softer during myopia and using a close-to-primate animal model, the tree shrew, to test safer ways to stiffen it. They plan to boost the eye's own collagen crosslinking by increasing an enzyme called lysyl oxidase with copper salts, since an earlier chemical (genipin) worked but had side effects. The team also examines signals from the edge of the retina that may trigger scleral changes and compares myopia, farsightedness, and aging effects. The work aims to find approaches that could later be tried in people to slow or stop the eyeball stretching behind worsening nearsightedness.
Who could benefit from this research
Good fit: Ideal candidates for future human testing would be people whose myopia is actively getting worse, often children or young adults with progressive nearsightedness.
Not a fit: People whose nearsightedness is stable or whose vision problems are unrelated to scleral remodeling are unlikely to benefit directly from this research now.
Why it matters
Potential benefit: If successful, this work could lead to safer treatments that slow or stop progressive nearsightedness and lower the risk of serious vision complications.
How similar studies have performed: Prior animal studies showed artificial crosslinking (genipin) can slow eye elongation but caused adverse effects, so the copper-driven approach is newer and less proven.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Grytz, Rafael — University of Alabama at Birmingham
- Study coordinator: Grytz, Rafael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.